Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PPP5C | P53041 | 2/20 | 0.47 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.47 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584689 | 0.89 | HTT (0.54) | HTTLMNAHRH3TSHRSMN1; SMN2 | |
| SCHEMBL25629645 | 0.89 | HTT (0.54) | HTTLMNAHRH3TSHRSMN1; SMN2 | |
| SCHEMBL20683271 | 0.89 | HTT (0.64) | HTTLMNAHRH3TSHRSMN1; SMN2 | |
| SCHEMBL2075903 | 0.86 | HTT (0.81) | HTTLMNATSHRALDH1A1HPGD | |
| SCHEMBL2077746 | 0.85 | TSHR (0.65) | HTTLMNATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL8194135 | 0.84 | HTT (0.71) | HTTLMNATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3595898 | 0.82 | TSHR (0.52) | HTTLMNAHRH3TSHRSMN1; SMN2 | |
| SCHEMBL4036891 | 0.82 | TSHR (0.52) | HTTLMNAHRH3TSHRSMN1; SMN2 | |
| SCHEMBL18415359 | 0.82 | HPGD (0.68) | HTTLMNAHRH3TSHRSMN1; SMN2 | |
| SCHEMBL12632672 | 0.82 | LMNA (0.79) | HTTLMNATSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121413-A1 | NOVEL BICYCLIC HETEROCYCLYL COMPOUND AND USE THEREOF | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023093832-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海济煜医药科技有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190031647-A1 | RAC INHIBITORS | Geneyus LLC (US) | 2019-01-31 | — | — | US | disclosed |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HTT 4246/4885LMNA 2697/4885HRH3 1340/4885 |
| US-20190031647-A1 | RAC INHIBITORS | ARHGDIB, ARHGDIA, RAC1 | HTT 3520/4885LMNA 3071/4885HRH3 2631/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | HTT 3810/4885LMNA 2693/4885HRH3 1469/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | HTT 292/4885LMNA 2237/4885HRH3 75/4885 |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | HTT 4246/4885LMNA 2697/4885HRH3 1340/4885 |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HTT 4246/4885LMNA 2697/4885HRH3 1340/4885 |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | HTT 4346/4885LMNA 2739/4885HRH3 495/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | HTT 3871/4885LMNA 2727/4885HRH3 1487/4885 |
| US-10472352-B2 | Rac inhibitors | ARHGDIB, ARHGDIA, RAC1 | HTT 3520/4885LMNA 3071/4885HRH3 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.